Ligand buys Ryjunea royalty, milestone interest from Sydnexis for $23 million

• Ligand Pharmaceuticals bought a 100% interest in Sydnexis payment rights tied to Santen’s Ryjunea for a USD 23 million upfront payment.
• Deal delivers an ascending tiered royalty on Ryjunea net sales in EMEA, ranging from low-double-digits to high-teens.
• Transaction also includes certain milestone payments under the existing Sydnexis-Santen license agreement.
• Ryjunea is a once-nightly low-dose atropine eye drop to slow pediatric myopia progression, approved in the EU in June 2025.
• Sydnexis keeps commercial rights outside Santen-licensed territories, including the U.S.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ligand Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220700PRIMZONEFULLFEED9830979) on September 22, 2026, and is solely responsible for the information contained therein.